Diamonds and Dogs
6/26/12ValueClick Inc. (VCLK)
ValueClick lost some of its value today, down 7.24% at $14.47. Shares of the internet advertising company fell after an analyst downgraded the stock on concerns about the advertising climate. Piper Jaffray analyst Mark Zgutowicz cut his rating on the company to "Neutral" from "Overweight," saying Internet ad buying is shifting to online exchanges. He now sees ValueClick's revenue growing at 7 percent year over year for the rest of 2012, down from a previous estimate of 9 percent. Earlier today shares dropped as low as $13.96. That's very close to the 52-week low of $13.35 which the stock hit last August.
Supernus Pharmaceuticals Inc. (SUPN)
Supernus had a super day up an enormous 114.19% at $12.23. Shares of the company more than doubled in price after the specialty drug maker said regulators have moved closer to granting final approval to its potential epilepsy treatment Trokendi XR. Trokendi XR is an extended-release version of the epilepsy treatment known generically as topiramate. Trokendi is designed to be taken once a day, while the older medication must be taken several times daily. The Food and Drug Administration gave tentative approval for the drug and told Supernus it would require no additional clinical trials. Final approval depends on whether the company can resolve "a marking exclusivity issue" tied to a specific pediatric population.